Nicotinic receptors play an important role in the regulation of neurotransmission in the CNS and their dysfunction has been related to a number of severe brain pathologies. As a result, novel ligands for neuronal nicotinic receptors, in particular for the two major α4β2 and α7 brain subtypes, may have a great potential for the treatment of several neurodegenerative disorders. Nicotine, the prototype of nicotinic agonists, has inspired the design of novel nicotinoids, mainly differing by the nature of the hydrogen bond acceptor and π-electron-rich group (HBA/π), that is 3-pyridinyl in nicotine, and/or by conformational flexibility. Recently, we have reported the synthesis and the binding affinity, for α4β2 and α7 nicotinic subtypes, of all the stereiosomers of 1,4-benzodioxane bearing a 2-pyrrolidinyl substituent at the 2-position (1).1 The designed structure, which can be seen as a rigidified analogue of nicotinic ligands such as prolinol phenyl ethers, is characterized by the presence of two vicinal stereocentres. These are connected by the sole bond, whose rotation is relevant to molecule conformation, and are placed in proximity of the critical cationic head with important consequences on the mutual disposition of N+ and HBA/π. Prompted by the finding that two of the four benzodioxane stereoisomers bind at α4β2 nicotinic receptor with submicromolar affinity, we designed new structures in which benzodioxane is replaced with piridodioxane (2) or bear a hydroxyl group at 7 position (3). Herein, we report the synthesis, the binding affinity for neuronal nicotinic receptors subtypes, the docking analysis of all the stereoisomers of 2 and 3 and discussing the structure-activity relationships.

SYNTHESIS AND BINDING AFFINITY OF NEW HIGHLY SELECTIVE alpha4beta2 NICOTINIC LIGANDS / M. Binda, C. Bolchi, R. Ferrara, L. Fumagalli, C. Gotti, M. Pallavicini, L. Pucci, E. Valoti, G. Vistoli. ((Intervento presentato al convegno Joint meeting on medicinal chemistry tenutosi a Budapest nel 2009.

SYNTHESIS AND BINDING AFFINITY OF NEW HIGHLY SELECTIVE alpha4beta2 NICOTINIC LIGANDS

M. Binda;C. Bolchi;R. Ferrara;L. Fumagalli;M. Pallavicini;E. Valoti;G. Vistoli
2009

Abstract

Nicotinic receptors play an important role in the regulation of neurotransmission in the CNS and their dysfunction has been related to a number of severe brain pathologies. As a result, novel ligands for neuronal nicotinic receptors, in particular for the two major α4β2 and α7 brain subtypes, may have a great potential for the treatment of several neurodegenerative disorders. Nicotine, the prototype of nicotinic agonists, has inspired the design of novel nicotinoids, mainly differing by the nature of the hydrogen bond acceptor and π-electron-rich group (HBA/π), that is 3-pyridinyl in nicotine, and/or by conformational flexibility. Recently, we have reported the synthesis and the binding affinity, for α4β2 and α7 nicotinic subtypes, of all the stereiosomers of 1,4-benzodioxane bearing a 2-pyrrolidinyl substituent at the 2-position (1).1 The designed structure, which can be seen as a rigidified analogue of nicotinic ligands such as prolinol phenyl ethers, is characterized by the presence of two vicinal stereocentres. These are connected by the sole bond, whose rotation is relevant to molecule conformation, and are placed in proximity of the critical cationic head with important consequences on the mutual disposition of N+ and HBA/π. Prompted by the finding that two of the four benzodioxane stereoisomers bind at α4β2 nicotinic receptor with submicromolar affinity, we designed new structures in which benzodioxane is replaced with piridodioxane (2) or bear a hydroxyl group at 7 position (3). Herein, we report the synthesis, the binding affinity for neuronal nicotinic receptors subtypes, the docking analysis of all the stereoisomers of 2 and 3 and discussing the structure-activity relationships.
2009
Settore CHIM/08 - Chimica Farmaceutica
SYNTHESIS AND BINDING AFFINITY OF NEW HIGHLY SELECTIVE alpha4beta2 NICOTINIC LIGANDS / M. Binda, C. Bolchi, R. Ferrara, L. Fumagalli, C. Gotti, M. Pallavicini, L. Pucci, E. Valoti, G. Vistoli. ((Intervento presentato al convegno Joint meeting on medicinal chemistry tenutosi a Budapest nel 2009.
Conference Object
File in questo prodotto:
File Dimensione Formato  
bolchi_abstract.doc

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 35 kB
Formato Microsoft Word
35 kB Microsoft Word Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/161015
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact